On the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, a session on tyrosine kinase inhibitors in treating chronic myelogenous leukemia ...
FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical stage oncology company, today announced that data from the ongoing ...
Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP). This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This ...
The MarketWatch News Department was not involved in the creation of this content. 64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy ...
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy One hundred sixteen patients in durable CGCR, and ...
The industry successfully implemented the mortgage market review with little impact on lending, which grew by more than 15 per cent in 2014, the Council of Mortgage Lenders reports. Today (9 December) ...
Life-long therapy with tyrosine kinase inhibitors (TKIs) is still the consensus treatment for patients with chronic myeloid leukemia (CML), but researchers are examining the feasibility of ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An ...
There may be some disruption to the monthly pattern of mortgage activity while the Mortgage Market Review (MMR) procedures bed down, the Council of Mortgage Lenders has warned. CML reported gross ...
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts ELVN-001 continues to demonstrate a favorable ...
A poster session December 7, 2014, at the 56th Annual Meeting of the American Society of Hematology in San Francisco was dedicated to trials evaluating therapeutic options in chronic myelogenous ...
HOUSTON -- An early molecular or cytogenetic response correlated with better long-term survival in heavily pretreated chronic-phase chronic myeloid leukemia (CML) treated with the BCR-ABL inhibitor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results